Mesnex Dosage
Generic name: MESNA 400mg
Dosage form: tablet, film coated
Drug class: Antineoplastic detoxifying agents
Medically reviewed by Drugs.com. Last updated on Dec 11, 2023.
Intravenous Dosing
MESNEX may be given on a fractionated dosing schedule of three bolus intravenous injections as outlined below.
MESNEX injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage weight by weight (w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide. The total daily dose of MESNEX is 60% of the ifosfamide dose. The recommended dosing schedule is outlined below in Table 1.
|
|||
|
0 Hours |
4 Hours |
8 Hours |
Ifosfamide |
1.2 g/m2 |
– |
– |
MESNEX injection* |
240 mg/m2 |
240 mg/m2 |
240 mg/m2 |
Intravenous and Oral Dosing
MESNEX may be given on a fractionated dosing schedule of a single bolus injection followed by two oral administrations of MESNEX tablets as outlined below.
MESNEX injection is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration. MESNEX tablets are given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide. The total daily dose of MESNEX is 100% of the ifosfamide dose. The recommended dosing schedule is outlined in Table 2.
|
|||
|
0 Hours |
2 Hours |
6 Hours |
Ifosfamide |
1.2 g/m2 |
– |
– |
MESNEX injection* |
240 mg/m2 |
– |
– |
MESNEX tablets |
– |
480 mg/m2 |
480 mg/m2 |
The efficacy and safety of this ratio of intravenous and oral MESNEX has not been established as being effective for daily doses of ifosfamide higher than 2 g/m2.
Patients who vomit within two hours of taking oral MESNEX should repeat the dose or receive intravenous MESNEX.
Monitoring for Hematuria
Maintain adequate hydration and sufficient urinary output, as required for ifosfamide treatment, and monitor urine for the presence of hematuria. If severe hematuria develops when MESNEX is given according to the recommended dosage schedule, dosage reductions or discontinuation of ifosfamide therapy may be required.
Preparation for Intravenous Administration and Stability
Preparation
Determine the volume of MESNEX injection for the intended dose.
Dilute the volume of MESNEX injection for the dose in any of the following fluids to obtain a final concentration of 20 mg/mL:
- •
- 5% Dextrose Injection, USP
- •
- 5% Dextrose and 0.2% Sodium Chloride Injection, USP
- •
- 5% Dextrose and 0.33% Sodium Chloride Injection, USP
- •
- 5% Dextrose and 0.45% Sodium Chloride Injection, USP
- •
- 0.9% Sodium Chloride Injection, USP
- •
- Lactated Ringer’s Injection, USP
Stability
The MESNEX injection multidose vials may be stored and used for up to 8 days after initial puncture.
Store diluted solutions at 25°C (77°F). Use diluted solutions within 24 hours.
Do not mix MESNEX injection with epirubicin, cyclophosphamide, cisplatin, carboplatin, and nitrogen mustard.
The benzyl alcohol contained in MESNEX injection vials can reduce the stability of ifosfamide. Ifosfamide and MESNEX may be mixed in the same bag provided the final concentration of ifosfamide does not exceed 50 mg/mL. Higher concentrations of ifosfamide may not be compatible with MESNEX and may reduce the stability of ifosfamide.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Any solutions which are discolored, hazy, or contain visible particulate matter should not be used.
More about Mesnex (mesna)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- During pregnancy
- Generic availability
- Drug class: antineoplastic detoxifying agents
- Breastfeeding
- En español
Patient resources
- Mesnex oral/injection drug information
- Mesnex (Mesna Intravenous) (Advanced Reading)
- Mesnex (Mesna Oral) (Advanced Reading)
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.